Novavax (NVAX) versus ChemoCentryx (CCXI) Head to Head Review

Novavax (NASDAQ: NVAX) and ChemoCentryx (NASDAQ:CCXI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Valuation & Earnings

How to Become a New Pot Stock Millionaire

This table compares Novavax and ChemoCentryx’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novavax $31.18 million 22.05 -$183.76 million ($0.63) -3.17
ChemoCentryx $82.50 million 8.37 $17.61 million $0.36 39.22

ChemoCentryx has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than ChemoCentryx, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Novavax and ChemoCentryx, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novavax 1 4 3 0 2.25
ChemoCentryx 0 1 1 0 2.50

Novavax currently has a consensus price target of $3.37, indicating a potential upside of 68.57%. ChemoCentryx has a consensus price target of $16.00, indicating a potential upside of 13.31%. Given Novavax’s higher probable upside, equities research analysts clearly believe Novavax is more favorable than ChemoCentryx.

Insider & Institutional Ownership

39.2% of Novavax shares are held by institutional investors. Comparatively, 48.4% of ChemoCentryx shares are held by institutional investors. 4.0% of Novavax shares are held by company insiders. Comparatively, 26.2% of ChemoCentryx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Novavax and ChemoCentryx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Novavax -589.46% N/A -54.30%
ChemoCentryx N/A 35.06% 11.71%

Volatility and Risk

Novavax has a beta of 2.5, indicating that its stock price is 150% more volatile than the S&P 500. Comparatively, ChemoCentryx has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500.

Summary

ChemoCentryx beats Novavax on 10 of the 14 factors compared between the two stocks.

Novavax Company Profile

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

ChemoCentryx Company Profile

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Analysts Anticipate PennantPark Investment Co.  Will Post Quarterly Sales of $27.23 Million
Zacks: Analysts Anticipate PennantPark Investment Co. Will Post Quarterly Sales of $27.23 Million
RSP Permian  Given a $69.00 Price Target by Stephens Analysts
RSP Permian Given a $69.00 Price Target by Stephens Analysts
Sandler O’Neill Analysts Give Simmons First National  a $35.00 Price Target
Sandler O’Neill Analysts Give Simmons First National a $35.00 Price Target
Wells Fargo Downgrades Emergent BioSolutions  to Market Perform
Wells Fargo Downgrades Emergent BioSolutions to Market Perform
Targa Resources  PT Set at $53.00 by Seaport Global Securities
Targa Resources PT Set at $53.00 by Seaport Global Securities
Cognex  Raised to Buy at Zacks Investment Research
Cognex Raised to Buy at Zacks Investment Research


© 2006-2018 Ticker Report. Google+.